journal
MENU ▼
Read by QxMD icon Read
search

Current Medical Research and Opinion

journal
https://www.readbyqxmd.com/read/28644104/the-association-between-blood-eosinophil-count-and-benralizumab-efficacy-for-patients-with-severe-uncontrolled-asthma-subanalyses-of-the-phase-iii-sirocco-and-calima-studies
#1
Mitchell Goldman, Ian Hirsch, James G Zangrilli, Paul Newbold, Xiao Xu
OBJECTIVE: Benralizumab, an anti-eosinophilic monoclonal antibody, in combination with high-dosage inhaled corticosteroids and long-acting β2-agonists (ICS/LABA) significantly reduced asthma exacerbations, improved lung function, and reduced symptoms for patients with severe, uncontrolled asthma with blood eosinophil counts ≥300 cells/µL in the Phase III SIROCCO and CALIMA studies. To understand the efficacy and safety of benralizumab for patients with eosinophil-driven disease with blood eosinophil counts lower than 300 cells/µL, we evaluated the effect of applying an eosinophil cutoff of ≥150 cells/µL...
June 23, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28644095/impact-of-adherence-to-antidepressants-on-healthcare-outcomes-and-costs-among-patients-with-type-2-diabetes-and-comorbid-major-depressive-disorder
#2
Charles Vega, Russell V Becker, Lisa Mucha, Betty H Lorenz, Michael T Eaddy, Augustina O Ogbonnaya
OBJECTIVE: To evaluate the association between adherence to antidepressants and an effect on clinical outcomes and healthcare costs in patients with major depressive disorder (MDD) and comorbid type 2 diabetes (T2D). METHODS: This retrospective study used MarketScan claims data from January 2012 to March 2014. Study entry was the first claim for an antidepressant and a diagnosis code for MDD and T2D in the prior 6 months. Adherence and persistence to antidepressant therapy in the first 180 days were defined as medication possession ratio (MPR) ≥80% and length of therapy (LOT), with no treatment gap of >15 days, respectively...
June 23, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28644048/risk-of-major-bleeding-in-patients-with-non-valvular-atrial-fibrillation-treated-with-oral-anticoagulants-a-systematic-review-of-real-world-observational-studies
#3
S Deitelzweig, C Farmer, X Luo, L Vo, X Li, M Hamilton, R Horblyuk, A Ashaye
OBJECTIVE: To conduct a systematic review of real-world (RWD) studies comparing the risk of major bleeding (MB) among patients with non-valvular atrial fibrillation (NVAF) on direct oral anticoagulants (DOACs) or warfarin Methods: MEDLINE, Embase, NHS-EED, and EconLit were searched for RWD studies published between January 2003 and November 2016 comparing MB risk among DOACs and warfarin. Proceedings of clinical conferences from 2012-2016 were reviewed. RESULTS: A total of 4,218 citations were identified, 26 of which met eligibility criteria...
June 23, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28641023/cardiovascular-event-incidence-and-cost-in-type-2-diabetes-mellitus-a-medicare-claims-based-actuarial-analysis
#4
Kathryn Fitch, Tyler Engel, Stephen Sander, Effie Kuti, Helen Blumen
OBJECTIVE: Assess the economic burden of cardiovascular events in Medicare beneficiaries with type 2 diabetes mellitus (T2DM). METHODS: This claims-based actuarial analysis queried 2013 and 2014 Medicare 5% Samples, defining a denominator of fee-for-service beneficiaries. Average per patient per month allowed cost ($PPPM) was calculated for T2DM, demographically adjusted non-T2DM, and denominator. Per member per month allowed cost ($PMPM) was calculated by dividing total population cost by member months in the denominator...
June 22, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28635338/risk-of-stroke-systemic-embolism-major-bleeding-and-associated-costs-in-non-valvular-atrial-fibrillation-patients-who-initiated-apixaban-dabigatran-or-rivaroxaban-compared-with-warfarin-in-the-united-states-medicare-population
#5
Alpesh Amin, Allison Keshishian, Jeffrey Trocio, Oluwaseyi Dina, Hannah Le, Lisa Rosenblatt, Xianchen Liu, Jack Mardekian, Qisu Zhang, Onur Baser, Lien Vo
OBJECTIVE: To compare the risk and cost of stroke/systemic embolism (SE) and major bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular atrial fibrillation (NVAF) patients. METHODS: Patients (≥65 years) initiating warfarin or DOACs (apixaban, rivaroxaban, and dabigatran) were selected from the Medicare database from 01/01/2013-12/31/2014. Patients initiating each DOAC were matched 1:1 to warfarin patients using propensity score matching to balance demographics and clinical characteristics...
June 21, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28635331/network-meta-analysis-of-liraglutide-versus-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-in-japanese-patients
#6
Dieter Ayers, Steve Kanters, Rachel Goldgrub, Monica Hughes, Ryo Kato, Nana Kragh
AIMS: To determine the comparative efficacy and safety of liraglutide and dipeptidyl peptidiase-4 (DPP-4) inhibitors as antidiabetics for Japanese patients with uncontrolled type 2 diabetes (T2DM). METHODS AND MATERIALS: We searched for randomized-controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016. We extracted data on trial and patient characteristics, and the following outcomes: HbA1c, weight, patients meeting HbA1c <7%, patients experiencing hypoglycemic events, microalbuminuria, estimated glomerular filtration rate (eGFR) and creatinine...
June 21, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28532239/status-and-trend-analysis-of-prophylactic-usage-of-recombinant-factor-viii-in-chinese-pediatric-patients-with-hemophilia-a-recare-a-retrospective-phase-iv-non-interventional-study
#7
Changgang Li, Xinsheng Zhang, Yongqiang Zhao, Runhui Wu, Qun Hu, Vicky Xu, Jing Sun, Renchi Yang, Xiaojing Li, Rongfu Zhou, Shinmei Lian, Jian Gu, Junde Wu, Qingsong Hou
BACKGROUND: No study has reported the status and chronological trend of prophylactic recombinant factor VIII (rFVIII) use in Chinese pediatric patients with hemophilia A (HA). OBJECTIVE: We aimed to analyze the status and trend of rFVIII-containing prophylaxis in Chinese pediatric patients with HA. METHODS: ReCARE (Retrospective study in Chinese pediatric hemophilia A patients with rFVIII contained REgular prophylaxis) was a retrospective study conducted in 12 hemophilia treatment centers across China...
June 21, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28631945/vildagliptin-any-effect-on-non-alcoholic-fatty-liver-disease-and-serum-uric-acid-re-shelbaya-s-rakha-s-effectiveness-and-safety-of-vildagliptin-and-vildagliptin-add-on-to-metformin-in-real-world-settings-in-egypt-results-from-the-guard-study-curr-med-res-opin
#8
https://www.readbyqxmd.com/read/28532169/impact-of-metoprolol-treatment-on-cardiac-function-and-exercise-tolerance-in-heart-failure-patients-with-neuropsychiatric-disorders
#9
Jingjing Huang, Ran Zhang, Xuelu Liu, Yong Meng
OBJECTIVE: To investigate the impact of neuropsychiatric disorders on the effect of metoprolol on cardiac and motor function in chronic heart failure (CHF) patients. METHODS: From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23.75 or 47.5 mg, once daily, orally) at the Second Affiliated Hospital of Kunming Medical University. Mental status was confirmed by means of the Hospital Anxiety and Depression Scale (HADS) and the Copenhagen Burnout Inventory (CBI) scale...
June 19, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28521534/objective-measurements-of-pelvic-venous-reflux-and-stratification-of-severity-of-venous-reflux-in-pelvic-congestion-syndrome-due-to-pelvic-venous-reflux
#10
Mark S Whiteley
No abstract text is available yet for this article.
June 19, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28613952/healthcare-costs-among-adults-with-type-2-diabetes-initiating-saxagliptin-or-linagliptin-a-us-based-claims-analysis
#11
Amanda M Kong, Sepehr Farahbakhshian, Trudy Pendergraft, Matthew A Brouillette, Biswarup Mukherjee, David M Smith, John J Sheehan
OBJECTIVE: To compare healthcare costs of adults with type 2 diabetes (T2D) after initiation of saxagliptin or linagliptin, two antidiabetic medications in the dipeptidyl peptidase-4 inhibitors medication class. METHODS: Patients with T2D who were at least 18 years old and initiated saxagliptin or linagliptin (index date) between 6/1/2011 and 6/30/2014 were identified in the MarketScan Commercial and Medicare Supplemental Databases. All-cause healthcare costs and diabetes-related costs (T2D diagnosis on a medical claim and/or an antidiabetic medication claim) were measured in the 1-year follow-up period...
June 14, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604117/efficacy-and-safety-of-post-docetaxel-therapies-in-metastatic-castrate-resistant-prostate-cancer-a-systematic-review-of-the-literature
#12
Nicholas Summers, Jacqueline Vanderpuye-Orgle, Marcia Reinhart, Meghan Gallagher, Oliver Sartor
OBJECTIVE: Prostate cancer is a highly prevalent form of cancer in older men and is one of the leading causes of death from cancer in men across the globe. Many therapeutic agents have been approved for patients with metastatic castrate-resistant prostate cancer (mCRPC), particularly as a post-docetaxel treatment strategy. The objective of this systematic literature review was to assess published efficacy and safety data for select mCRPC therapies - such as abiraterone, cabazitaxel, and enzalutamide - in the post-docetaxel setting...
June 12, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28537506/efficacy-and-safety-of-tapentadol-prolonged-release-for-moderate-to-severe-chronic-osteoarthritis-knee-pain-a-pooled-analysis-of-two-double-blind-randomized-placebo-and-oxycodone-controlled-release-controlled-studies
#13
Bernd Lange, Detlef von Zabern, Christian Elling, Cecile Dubois
OBJECTIVE: To compare efficacy and safety of tapentadol prolonged-release (PR) and oxycodone-controlled release (CR) in moderate-to-severe chronic osteoarthritis knee pain. METHODS: Data from two double-blind, randomized, placebo- and oxycodone CR-controlled phase 3 studies with a 3-week titration period and 12-week controlled dose adjustment maintenance period were pooled. Primary efficacy end-points were change from baseline in average pain intensity at week 12 (US end-point) and over the entire maintenance period (non-US end-point)...
June 11, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28537501/tapentadol-prolonged-release-for-moderate-to-severe-chronic-osteoarthritis-knee-pain-a-double-blind-randomized-placebo-and-oxycodone-controlled-release-controlled-study
#14
Alain Serrie, Bernd Lange, Achim Steup
OBJECTIVE: To assess efficacy and safety of tapentadol prolonged release (PR) for moderate-to-severe chronic osteoarthritis knee pain. METHODS: Patients (n = 990) were randomized (1:1:1) to tapentadol PR, oxycodone controlled release (CR; reference compound for assay sensitivity), or placebo for a double-blind 3-week titration and 12-week maintenance period. Primary efficacy end-points were change from baseline in average pain intensity at week 12 of maintenance (US end-point) and over the entire maintenance period (non-US end-point) with "last observation carried forward" as imputation method for missing scores...
June 11, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28537467/dose-escalation-of-biologics-in-crohn-s-disease-critical-review-of-observational-studies
#15
Thomas R Einarson, Basil G Bereza, Xin Ying Lee, Filippo Lelli
BACKGROUND: Biologics used to treat Crohn's disease (CD) may lose their effect over time, requiring dose escalation. Little information is available on this topic. AIM: To summarize rates of dose escalation, duration, de-escalation in observational studies of CD in adults treated with adalimumab, infliximab, and vedolizumab in Europe. METHODS: Two independent investigators searched Medline and Embase for observational studies published in 1998-2015 and proceedings from four major scientific meetings...
June 11, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604119/vorapaxar-in-secondary-prevention-where-we-stand
#16
Anastazia Kei, Moses Elisaf
This editorial accompanies an original article being published by the Current Medical Research and Opinion (CMRO) journal, entitled "State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease". In this editorial we consider some aspects of the use of vorapaxar in secondary prevention in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD).
June 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604116/the-cognitive-decline-in-older-patients-with-end-stage-renal-disease-cope-study-rationale-and-design
#17
Noeleen Berkhout-Byrne, Marije H Kallenberg, André Gaasbeek, Ton J Rabelink, Sebastiaan Hammer, Mark A van Buchem, Matthias J van Osch, Lucia J M Kroft, Henk Boom, Simon P Mooijaart, Marjolijn van Buren
BACKGROUND: Older patients with end stage renal disease (ESRD) are at increased risk for cognitive decline, but detailed studies of the magnitude of cognitive decline on dialysis or comprehensive conservative management (CCM) are lacking and the underlying pathophysiological mechanisms have poorly been studied. OBJECTIVE: To describe the rationale and design of the COPE study. Study objectives are firstly to examine the severity of cognitive impairment in older patients reaching ESRD before dialysis and the rate of decline after dialysis or CCM initiation...
June 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604115/a-randomized-controlled-trial-comparing-a-xyloglucan-based-nasal-spray-with-saline-in-adults-with-symptoms-of-rhinosinusitis
#18
Alessandro Allegrini, Daniele Pavone, Fulvio Carluccio
BACKGROUND: This study assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray in the treatment of symptoms of rhinosinusitis. METHODOLOGY: In this randomized, double-blind study, 40 patients with itching, nasal congestion or continuous sneezing and a Total Nasal Symptom Score (TNSS) of ≥8 were randomized to 2 weeks' treatment with a xyloglucan-based nasal spray ('xyloglucan') or a physiological saline nasal spray ('saline'). Assessments included the TNSS, rhinosinusitis severity index, nocturnal awakenings, use of rescue medication, safety and tolerability...
June 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604112/correlates-of-basal-insulin-persistence-among-insulin-na%C3%A3-ve-people-with-type-2-diabetes-results-from-a-multi-national-survey
#19
Mark Peyrot, Magaly Perez-Nieves, Jasmina Ivanova, Dachuang Cao, Luke Schmerold, Samaneh Kalirai, Irene Hadjiyianni
BACKGROUND AND OBJECTIVE: People with T2DM who initiate basal insulin therapy often stop therapy temporarily or permanently soon after initiation. This study analyzes the reasons for and correlates of stopping and restarting basal insulin therapy among people with T2DM. METHODS: An online survey was completed by 942 insulin-naïve adults with self-reported T2DM from Brazil, France, Germany, Japan, Spain, UK, and US. Respondents had initiated basal insulin therapy within the 3-24 months before survey participation and met criteria for one of three persistence groups: continuers had no gaps of ≥7 days in basal insulin treatment; interrupters had at least one gap in insulin therapy of ≥7 days within the first 6 months after initiation and had since restarted basal insulin; and discontinuers stopped using basal insulin within the first 6 months after initiation and had not restarted...
June 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604111/basal-insulin-initiation-use-and-experience-among-people-with-type-2-diabetes-mellitus-with-different-patterns-of-persistence-results-from-a-multi-national-survey
#20
Magaly Perez-Nieves, Jasmina I Ivanova, Irene Hadjiyianni, Chen Zhao, Dachuang Cao, Luke Schmerold, Samaneh Kabul, Sarah King, Amy M DeLozier, Howard G Birnbaum, Mark Peyrot
BACKGROUND AND OBJECTIVE: People with type 2 diabetes mellitus (T2DM) often interrupt basal insulin treatment soon after initiation. This study aimed to describe the experiences during and after basal insulin initiation among people with T2DM with different persistence patterns. METHODS: Adults with T2DM from France, Germany, Spain, UK, US, Brazil, and Japan were identified from consumer panels for an online survey. Respondents who initiated basal insulin 3-24 months prior to survey date,were categorized as continuers (no gaps of ≥7 days in insulin treatment); interrupters (first gap ≥7 days within 6 months of initiation and restarted insulin); and discontinuers (stopped insulin for ≥7 days within 6 months of initiation without restarting)...
June 10, 2017: Current Medical Research and Opinion
journal
journal
22988
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"